About
The Journal "Obstetrics and Gynecology"Journal HistoryAims and ScopePolicies on Conflict of Interest, Human and Animal Rights, and Informed ConsentEditorial ProcessData sharing statementAdvertising PolicyThe Process for Handling Cases Requiring Corrections, Retractions, and Editorial Expressions of ConcernEditorial BoardEditorial CounsilInformation for ProfessionalsNewsContacts
ArchiveEthical StandardsSubscription
For authors
InstructionsInformed consent policyContract offerEASE GuidelinesICJME CriteriaWAME Recommendations on ChatGPT and Chatbots in Relation to Scholarly Publications
Reviewing
About
The Journal "Obstetrics and Gynecology"Journal HistoryAims and ScopePolicies on Conflict of Interest, Human and Animal Rights, and Informed ConsentEditorial ProcessData sharing statementAdvertising PolicyThe Process for Handling Cases Requiring Corrections, Retractions, and Editorial Expressions of ConcernEditorial BoardEditorial CounsilInformation for ProfessionalsNewsContacts
ArchiveEthical StandardsSubscription
For authors
InstructionsInformed consent policyContract offerEASE GuidelinesICJME CriteriaWAME Recommendations on ChatGPT and Chatbots in Relation to Scholarly Publications
Reviewing
Logout
Obstetrics and Gynegology2023№1
Results of bioequivalence studies on...

Results of bioequivalence studies on dienogest, progesterone, and levonorgestrel+estradiol in healthy volunteers after single dose intake during fasting

DOI
https://dx.doi.org/10.18565/aig.2022.304

Apolikhina I.A., Tarnaeva L.A., Kondratyeva N.E.

1) Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia, Moscow, Russia; 2) I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia, Moscow, Russia; 3) Pharmasyntez JSC, Moscow, Russia
The paper presents the results of three bioequivalence studies on DlyaZhens metri (dienogest), DlyaZhens pro (progesterone), DlyaZhens klimo (levonorgestrel + estradiol) manufactured by the “Farmasintez-Tyumen” LLC, Russia, and their corresponding original (reference) drugs Visanne (Bayer Pharma AG, Germany), Utrogestan (Besen Healthcare SA, Belgium), and Klimonorm (Jenapharm GmbH & Co. KG, Germany). The bioequivalence studies determined the pharmacokinetic parameters of dienogest, progesterone, and levonorgestrel + estradiol in the plasma of healthy volunteers after single oral dose intake of the compared drugs during fasting according to a 2-stage open-label randomized crossover regimen for dienogest and levonorgestrel + estradiol and according to 4-stage one for progesterone. The plasma concentration of the active ingredients of the drugs was analyzed by a highly sensitive and selective bioanalytical method using high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). The following pharmacological parameters (AUC0-t, AUC0-∞, AUC0-72, AUCresid, AUCresid%, Cmax, TCmax, T½, kel, f’, Cmax/AUC, and MRT) were calculated for the drugs analyzed. The 90% confidence intervals for the ratios of the geometric mean values of AUC0-t and Cmax were in the range from 80.00 to 125.00% in the bioequivalence studies of dienogest, progesterone, and levonorgestrel + estradiol.
Conclusion: The findings have led to the conclusions about the bioequivalence of the test and reference drugs, such as dienogest, progesterone, and levonorgestrel + estradiol. The safety profiles of the compared drugs were comparable.

Authors’ contributions: Apolikhina I.A. – development of the general concept of the article, literature search, manuscript writing, editing; Tarnayeva L.A. – literature search, text writing; Kondratyeva N.E. – research developer.
Conflicts of interest: The authors declare that there are no conflicts of interest.
Funding: The investigation has not been sponsored.
Acknowledgement: The authors express their gratitude to Irina A. Proskurina, Can. Med. Sci., Head of the Department Two for Drug Efficacy and Safety, Center for Examination and Control of Ready-Made Drugs, Research Center for Examination of Medicinal Products, Ministry of Health of Russia, for assistance in preparing the article.
For citation: Apolikhina I.A., Tarnaeva L.A., Kondratyeva N.E. Results of bioequivalence studies on dienogest, progesterone, and levonorgestrel+estradiol in healthy volunteers after single dose intake during fasting.
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2023; 1: 110-121 (in Russian)
https://dx.doi.org/10.18565/aig.2022.304

Keywords

bioequivalence
pharmacokinetic parameters
dienogest
progesterone
levonorgestrel + estradiol
DlyaZhens metri
DlyaZhens pro
DlyaZhens klimo
Full text (in Russian)

References

  1. Преамбула к Уставу (Конституции) Всемирной организации здравоохранения. [Preamble to the Charter (Constitution) of the World Health Organization. (in Russian)]. Available: www.who.int
  2. Сотникова Л.С., Удут Е.Н., Насырова Р.Ф., Тонких О.С. Современная терапия эндометриоза. Опыт применения визанны Проблемы репродукции. 2012; 6: 34-9. [Sotnikova L.S., Udut E.V., Nasyrova R.F., Tonkikh O.S. Modern methods of endometriosis therapy - the experience of visanne use. Russian Journal of Human Reproduction. 2012; (6): 34 9. (in Russian)].
  3. Giudice L.C. Endometriosis. N. Engl. J. Med. 2010; 362(25): 2389-98. https://dx.doi.org/10.1056/NEJMcp1000274.
  4. Holoch K.J., Lessey B.A. Endometriosis and infertility. Clin. Obstet. Gynecol. 2010; 53(2): 429-38. https://dx.doi.org/10.1097/GRF.0b013e3181db7d71.
  5. Littman E., Giudice L., Lathi R., Berker B., Milki A., Nezhat C. Role of laparoscopic treatment of endometriosis inpatients with failed in vitro fertilization cycles. Fertil. Steril. 2005; 84(6): 1574-8. https://dx.doi.org/10.1016/j.fertnstert.2005.02.059.
  6. Министерство здравоохранения Российской Федерации. Клинические рекомендации. Эндометриоз. М.; 2020. [Ministry of Health of the Russian Federation. Clinical guidelines. Endometriosis. Moscow; 2020. (in Russian)]. Available at: https://roag-portal.ru/recommendations_gynecology
  7. Allaire C. Endometriosis and infertility: a review. J. Reprod. Med. 2006;51(3): 164-8.
  8. Poleshuck E.L., Bair M.J., Kroenke K., Watts A., Tu X., Giles D.E. Pain and depression in gynecology patients. Psychosomatics. 2009; 50(3): 270-6. https://dx.doi.org/10.1176/appi.psy.50.3.270.
  9. Адамян Л.В., Кулаков В.И., Андреева Е.Н. Эндометриозы. М.: Медицина; 2006. 416c. [Adamyan L.V., Kulakov V.I., Andreeva E.N. Endometriosis. Moscow: Medicine; 2006. 416 p. (in Russian)].
  10. Leyland N., Casper R., Laberge P., Singh S.S.; SOGC. Endometriosis: diagnosis and management. J. Obstet. Gynaecol. Can. 2010; 32(Suppl. 2): S1-32.
  11. Practical bulletin no.114: management of endometriosis. Obstet. Gynecol. 2010; 116(1): 223-36. https://dx.doi.org/10.1097/AOG.0b013e3181e8b073.
  12. Australian Public Assessment Report for Dienogest. Proprietary Product Name: Visanne, Submission No: PM-2009-00539-3-5. Sponsor: Bayer Australia Ltd. September 2010.
  13. Sasagawa S., Shimizu Y., Kami H., Takeuchi T., Mita S., Imada K. et al. Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile. Steroids. 2008; 73(2): 222-31. https://dx.doi.org/10.1016/j.steroids.2007.10.003.
  14. Инструкция по медицинскому применению лекарственного препарата Визанна®, таблетки 2 мг. Государственный реестр лекарственных средств. [Instruction for the medical use of the drug Visanna®, tablets 2 mg. State Register of medicines. (in Russian)]. Available at: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=cb3e7b14-94ab-439e-ae5b-7ccc46d70b2a
  15. Klipping C., Duijkers I., Faustmann T.A., Klein S.F., Schuett B. Pharmacodynamic study of four oral dosages of dienogest. Fertil. Steril. 2010; 94(4, Suppl.): S181. https://dx.doi.org/10.1016/j.fertnstert.2010.07.708.
  16. Oettel M., Breitbarth H., Elger W., Gräser T., Hübler D., Kaufmann G. et al. The pharmacological profile of dienogest. Eur. J. Contracept. Reprod. Health Care. 1999; (4, Suppl. 1): 2-13. https://dx.doi.org/10.3109/13625189909085259.
  17. Moore C., Carol W., Gräser T., Mellinger U., Walter F. Influence of dienogest on ovulation in young fertile women. Clin. Drug Invest. 1999; 18: 271-8.
  18. Momoeda M., Harada T., Terakawa N., Aso T., Fukunaga M., Hagino H., Taketani Y. Long-term use of dienogest for the treatment of endometriosis. J. Obstet. Gynaecol. Res. 2009; 35(6): 1069-76. https://dx.doi.org/10.1111/j.1447-0756.2009.01076.x.
  19. Momoeda M., Taketani Y., Terakawa N., Aso T., Tsutani K. Randomized double-blind, multicentre, parallel-group dose–response study of dienogest in patients with endometriosis. Jpn. Pharmacol. Ther. 2007; 35(7): 769-83.
  20. Petraglia F., Hornung D., Seitz C., Faustmann T., Gerlinger C., Luisi S. et al. Reduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment. Arch. Gynecol. Obstet. 2011; 285(1): 167-73. https://dx.doi.org/10.1007/s00404-011-1941-7.
  21. Довжикова И.В., Луценко М.Т. Современные представления о роли прогестерона (обзор литературы). Бюллетень физиологии и патологии дыхания. 2016; 60: 94-104. https://dx.doi.org/10.12737/20128. [Dovzhikova I.V., Lutsenko M.T. Modern conceprs of progesterone role (review). Bulletin of Physiology and Pathology of Respiration. 2016; (60): 94-104. (in Russian)]. https://dx.doi.org/10.12737/20128.
  22. Тапильская Н.И., Гзгзян А.М., Коган И.Ю., Писарев В.В., Меркулов М.Е., Корнеева И.Е. Сравнительные фармакокинетические свойства и оценка безопасности воспроизведенного препарата прогестерона в форме вагинального геля: результаты открытого рандомизированного перекрестного исследования биоэквивалентности. Акушерство и гинекология. 2022; 8: 144-52. https://dx.doi.org/10.18565/aig.2022.8. 144-152. [Tapilskaya N.I., Gzgzyan A.M., Kogan I.Yu., Pisarev V.V., Merkulov M.E., Korneeva I.E. Pharmacokinetic properties and safety assessment of the generic vaginal gel progesterone preparation: results of an open-label, randomized, crossover bioequivalence study. Obstetrics and Gynecology. 2022; (8): 144-52. (in Russian)]. https://dx.doi.org/10.18565/aig.2022.8.144-152.
  23. Назаренко Т.А., Зыряева Н.А., Магамадова М.У. Эффективность гестагенов в зависимости от их состава и способа введения. Проблемы репродукции. 2013; 2: 20-5. [Nazarenko T.A., Zyriaeva N.A., Magamadova M.U. Gestagens efficacy according to their composition and the route of administration. Russian Journal of Human Reproduction. 2013; (2): 20-5. (in Russian)].
  24. Тихомиров А.Л., Лубнин Д.М. Сравнительная характеристика прогестерона и синтетических прогестинов в аспекте клинического использования при терапии прогестерондефицитных состояний. РМЖ. 2003; 16: 929. [Tikhomirov A.L., Lubnin D.M. Comparative characteristics of progesterone and synthetic progestins in terms of clinical use in the treatment of progesterone deficiency conditions. RMJ. 2003; (16): 929. (in Russian)].
  25. Инструкция по медицинскому применению лекарственного препарата Утрожестан®, капсулы, 100 мг, 200 мг. Государственный реестр лекарственных средств. [Instructions for the medical use of the drug Utrozhestan®, capsules, 100 mg, 200 mg. State Register of medicines. (in Russian)]. Available at: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=085efcda-3ec4-4f91-aa4b-573109d524cc
  26. Инструкция по медицинскому применению лекарственного препарата Климонорм®, набор таблеток, покрытых оболочкой, 2 мг и 0,15 мг+2 мг. Государственный реестр лекарственных средств. [Instructions for the medical use of the drug Klimonorm®, a set of coated tablets, 2 mg and 0,15 mg + 2 mg. State Register of medicines. (in Russian)]. Available at: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=d9a2a401-ace7-4984-bd18-2618510b961a
  27. Менопаузальная гормонотерапия и сохранение здоровья женщин зрелого возраста. Клинические рекомендации (Протоколы). М.; 2015. [Menopausal hormone therapy and maintaining the health of women of mature age. Clinical guidelines (Protocols). Moscow; 2015. (in Russian)].
  28. Краснопольский В.И., Зайдиева Я.З. Фармакологические и клинические аспекты менопаузальной гормонотерапии. Информационно-образовательное руководство. М.; 2016. [Krasnopolsky V.I., Zaidieva Ya.Z. Pharmacological and clinical aspects of menopausal hormone therapy. informational and educational guide. Moscow; 2016. (in Russian)].
  29. Кузнецова И.В., Якутова М.В. Жировой и углеводный обмен у женщин, использующих различные режимы заместительной гормональной терапии. РМЖ. Мать и дитя. 2008; 16(19): 1265. [Kuznetsova I.V., Yakutova M.V. Fat and carbohydrate metabolism in women using various regimens of hormone replacement therapy. PMJ. Mother and Child. 2008; 16(19): 1265. (in Russian)].
  30. Министерство здравоохранения и социального развития Российской Федерации, Федеральная служба по надзору в сфере здравоохранения и социального развития, Федеральное государственное учреждение «Научный центр экспертизы средств медицинского применения». Оценка биоэквивалентности лекарственных средств. Методические указания. М.; 2008. [Ministry of Health and Social Development of the Russian Federation, Federal Service for Surveillance in Healthcare and Social Development, Federal State Institution "Scientific Center for Expertise of Medicinal Products". Evaluation of bioequivalence of drugs. Methodical instructions. Moscow; 2008. (in Russian)].
  31. Миронов А.Н., Кукес В.Г., Петров В.И., Кузнецов А.Л., Горячев Д.В.., Ниязов Р.Р., Прокофьев А.Б., Недогода С.В., Фролов М.Ю., Шнайдер А. Изучение биоэквивалентности воспроизведенных лекарственных средств. В кн.: Руководство по экспертизе лекарственных средств. т. 1.М.: Гриф и К; 2014: 174-216. [Mironov A.N., Kukes V.G., Petrov V.I. et al. Study of bioequivalence of reproduced drugs. Guidelines for the examination of medicinal products. vol. 1. Moscow: Grif and K; 2014: 174-216. (in Russian)].
  32. Правила проведения исследований биоэквивалентности лекарственных препаратов в рамках Евразийского экономического союза (Решение Совета Евразийской экономической комиссии от 3 ноября 2016 г. № 85). [Rules for conducting bioequivalence studies of medicinal products within the framework of the Eurasian Economic Union (Decision of the Council of the Eurasian Economic Commission of November 3, 2016 No. 85). (in Russian)].
  33. Национальный стандарт Российской Федерации ГОСТР 52379-2005 «Надлежащая Клиническая Практика». [National standard of the Russian Federation GOSTR 52379-2005 "Good Clinical Practice". (in Russian)].
  34. Приказ Минздрава России от 1 апреля 2016 г. № 200н «Об утверждении правил надлежащей клинической практики». [Order of the Ministry of Health of Russia dated April 1, 2016 No. 200n “On approval of the rules of good clinical practice”. (in Russian)].
  35. Решение Совета Евразийской экономической комиссии № 79 от 03.11.2016 «Об утверждении Правил надлежащей клинической практики Евразийского экономического союза»). [Decision of the Council of the Eurasian Economic Commission No. 79 03.11.2016 "On approval of the rules of good clinical practice of the Eurasian Economic Union"). (in Russian)].
  36. ГРЛС, РКИ № 517 (08.10.2018). https://grls.rosminzdrav.ru/CIPermissionMini.aspx?CIStatementGUID=589899e1-b173-4482-9394-c0c9f817486c&CIPermGUID=543C6848-9F8A-4637-8708-ED490BD22578 [State Register of Medicines, randomized clinical trial No. 517 (08.10.2018). (in Russian). Available at: https://grls.rosminzdrav.ru/CIPermissionMini.aspx?CIStatementGUID=589899e1-b173-4482-9394-c0c9f817486c&CIPermGUID=543C6848-9F8A-4637-8708-ED490BD22578]
  37. ГРЛС, РКИ № 635 (08.12.2017). https://grls.rosminzdrav.ru/CIPermissionMini.aspx?CIStatementGUID=860023f9-151d-4d99-b11f-f7e87b35d4b8&CIPermGUID=8BF540C9-2B2E-4BC3-BD29-01A43F68A067 [State Register of Medicines, randomized clinical trial No. 635 (08.12.2017). (in Russian). Available at: https://grls.rosminzdrav.ru/CIPermissionMini.aspx?CIStatementGUID=860023f9-151d-4d99-b11f-f7e87b35d4b8&CIPermGUID=8BF540C9-2B2E-4BC3-BD29-01A43F68A067]
  38. ГРЛС, РКИ № 216 (11.05.2018). https://grls.rosminzdrav.ru/CIPermissionMini.aspx?CIStatementGUID=4dff306d-a273-4f58-8ad5-a7bc0c0bafb6&CIPermGUID=41870C50-173B-4EAC-BA41-15ABA690386F [State Register of Medicines, randomized clinical trial No. 635 (08.12.2017). (in Russian). Available at: https://grls.rosminzdrav.ru/CIPermissionMini.aspx?CIStatementGUID=4dff306d-a273-4f58-8ad5-a7bc0c0bafb6&CIPermGUID=41870C50-173B-4EAC-BA41-15ABA690386F]
  39. Кондратьева Н.Е. Исследование сравнительной фармакокинетики и биоэквивалентности препаратов Эторикоксиб 120 мг (АО «Фармасинтез», Россия) и Аркоксиа® 120 мг (Мерк Шарп и Доум Б.В., Нидерланды) в таблетках. Поликлиника. 2021; 2: 77-82. [Kondratieva N.E. A study of comparative pharmacokinetics and evaluate bioequivalences of Etoricoxib, film coated tablets, 120 mg (Pharmasyntez) and Arcoxia®, film coated tablets, 120 mg (Merck Sharp and Dome BV, Netherlands). Polyclinic. 2021; (2): 77-82. (in Russian)].
  40. Pickar J.H., Bon C., Amadio J.M., Mirkin S., Bernick B. Pharmacokinetics of the first combination 17β-estradiol/progesterone capsule in clinical development for menopausal hormone therapy. Menopause. 2015; 22(12): 1308-16. https://dx.doi.org/10.1097/GME.0000000000000467.
  41. Хохлов А.Л., Яичков И.И., Шитова А.М., Шитов Л.Н., Джурко Ю.А., Мирошников А.Е. Исследование сравнительной фармакокинетики таблетированных форм микофеноловой кислоты. Фармакокинетика и фармакодинамика. 2016; 4: 3-8. [Khokhlov A.L., Yaichkov I.I., Shitova A.M., Shitova L.N., Dzhurko Yu.A., Miroshnikov A.E. A comparative study of pharmacokinetics of coated tablets of mycophenolic acid. Pharmacokinetics and Pharmacodynamics. 2016; (4): 3-8. (in Russian)].

Received 08.12.2022

Accepted 27.01.2023

About the Authors

Inna A. Apolikhina, Dr. Med. Sci., Professor, Head of the Department of Aesthetic Gynecology and Rehabilitation, V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia; Professor at the Department of Obstetrics, Gynecology, Perinatology and Reproductology of the Institute of Professional Education, I.M. Sechenov 1st Moscow State Medical University, Ministry of Health of Russia (Sechenov University), i_apolikhina@oparina4.ru,
117997, Russia, Moscow, Ac. Oparin str., 4.
Liana A. Tarnaeva, resident, V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia,
+7(915)112-77-52, li.tarnaeva@ya.ru, 117997, Russia, Moscow, Ac. Oparin str., 4.
Natalya Е. Kondratyeva, PhD, Medical Director, Pharmasintez JSC, +7(916)849-71-32, moscow@pharmasyntez.com,
123100, Russia, Moscow, Presnenskaya nab., 12, Federation Tower (West), 42nd floor.

Similar Articles

№9 / 2020
Dobrokhotova Yu.E., Zubareva E.A., Borovikova E.I., Zalesskaya S.A., Kazantsev S.N.
Assessment of the functional activity of the corpus luteum in the prediction of early pregnancy complications
№9 / 2023
Bashmakova N.V., Khramtsova A.Yu., Dzhalilova E.R.
Therapeutic equivalence evaluation of bioequivalent and original micronized vaginal progesterone preparations in hormone replacement therapy in women undergoing frozen-thawed embryo transfer
№4 / 2020
Dubrovina S.O., Berlim Yu.D., Gimbut V.S., Vovkochina M.A.
Hormone therapy for functional ovarian cysts
№8 / 2023
Dumanovskaya M.R.
Results of bioequivalence studies on the drugs gestodene+ethinylestradiol and drospirenone+ethinylestradiol in healthy volunteers
№5 / 2021
Prokhorova O.V., Olina A.A., Tolibova G.Kh., Tral T.G.
Progesterone-induced blocking factor: from molecular biology to clinical medicine
By continuing to use our site, you consent to the processing of cookies that ensure the proper functioning of the site.